On May 15, Handok signed a joint advertising campaign agreement with Sanofi Pasteur to promote six of the latter’s vaccines in Korea, organizing a ceremony to mark the agreement on May 21. The latest contract will allow Handok to handle marketing for six more vaccines in addition to Vaxigrip Tetra® (quadrivalent influenza vaccine) and Vaxigrip (trivalent influenza vaccine), thereby boosting its vaccine portfolio.

The six vaccines Handok now newly handles are: AVAXIM® 160U injection for adults (hepatitis A); ADACEL® injection for adults (reduced diphtheria toxoid, tetanus toxoid, and acellular pertussis absorbed); Menactra® (meningococcal groups A, C, Y, and W-135 polysaccharide diphtheria toxoid conjugate); Imojev® injection (recombinant live-attenuated against Japanese encephalitis); Pentaxim® injection (absorbed diphtheria, tetanus toxoid, acellular pertussis, inactivated poliovirus, Hib-conjugate combined vaccine); and Tetraxim® injection (absorbed diphtheria, tetanus toxoid, acellular pertussis, and inactivated polio combined).

AVAXIM® 160U injection for adults, a hepatitis-A vaccine for teenagers and adults over the age of 16, boasts rapid serological conversion and high antibody titers. Menactra® injection vaccinates people between the age of nine months and 55 against four major meningococcal groups – A (common in Asia), C, Y, and W-135. Imojev® injection is the only injection-type vaccine against Japanese encephalitis approved in Korea for administration on adults and children alike.

Pentaxim® injection is a combined vaccine that vaccinates against five diseases: diphtheria, tetanus, acellular pertussis (DTaP), polio (IPV), and hemophilus influenza b (HiB). ADACEL® injection is a Tdap vaccine for people aged 11 to 64. Tetraxim® combines vaccinations against DTaP and IPV.